NASDAQ : PMN
ProMIS Neurosciences, Inc. — Key statistics
Healthcare · Biotechnology · Canada
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 26.90M |
| Enterprise Value | -26.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 8.97M |
| Shares Outstanding | 8.97M |
| Shares Change (YoY) | +272.11% |
| Shares Change (QoQ) | +40.05% |
| Owned by Insiders (%) | 11.59% |
| Owned by Institutions (%) | 45.53% |
| Float | 4.38M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.85 |
| Quick Ratio | 7.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -172.30% |
| Return on Assets (ROA) | -81.06% |
| Return on Invested Capital (ROIC) | -109.49% |
| Return on Capital Employed (ROCE) | -86.78% |
| Weighted Average Cost of Capital (WACC) | 2.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.84M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.25 |
| 52-Week Price Change | -71.09% |
| 50-Day Moving Average | 11.02 |
| 200-Day Moving Average | 12.87 |
| Relative Strength Index (RSI) | 26.60 |
| Average Volume (20 Days) | 285,613 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 245,838 |
| Short Previous Month | 238,584 |
| Short % of Shares Out | 2.74% |
| Short % of Float | 5.61% |
| Short Ratio (days to cover) | 7.04 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -35.66M |
| Operating Income | -42.93M |
| Pretax Income | -42.23M |
| Net Income | -42.23M |
| EBITDA | n/a |
| EBIT | -42.93M |
| Earnings Per Share (EPS) | -$8.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 53.46M |
| Total Debt | n/a |
| Net Cash | 53.46M |
| Net Cash Per Share | $5.96 |
| Equity (Book Value) | 49.40M |
| Book Value Per Share | 5.51 |
| Working Capital | 49.48M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -42.11M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -42.11M |
| FCF Per Share | -$4.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -272.11% |
| Shareholder Yield | -272.11% |
| Earnings Yield | -281.71% |
| FCF Yield | -156.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $44.98 |
| Price Target Difference | 1,399.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |